Equities
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.

  • Revenue in USD (TTM)29.78bn
  • Net income in USD1.90bn
  • Incorporated1925
  • Employees49.28k
  • Location
    Takeda Pharmaceutical Co Ltd4F, 2-1-1, Nihombashihon-choCHUO-KU 103-8668JapanJPN
  • Phone+81 332782111
  • Fax+81 332782000
  • Websitehttps://www.takeda.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Biogen Inc9.61bn1.62bn25.22bn7.57k15.641.5311.142.6211.0711.0765.83112.900.340.86044.581,269,155.005.7112.537.0114.8375.5983.0416.8026.930.80394.890.27780.00-3.32-6.07-61.89-23.58-18.87--
Bayer AG50.50bn-1.36bn25.36bn96.57k--0.66293.360.5021-1.29-1.2947.9636.330.39011.473.47472,438.70-1.04-1.79-1.42-2.3858.0759.02-2.67-4.800.85732.940.5651---6.115.33-170.87--1.19-47.66
Otsuka Holdings Co Ltd14.87bn993.02m34.71bn34.39k33.982.0520.142.33279.51279.514,183.344,641.150.6472.404.6865,998,690.004.424.805.595.8871.4268.216.848.361.53--0.117342.1616.149.33-9.188.079.271.92
Alnylam Pharmaceuticals, Inc.2.09bn-332.26m35.78bn2.10k--1,104.79--17.08-2.62-2.6216.520.25110.52083.578.41997,521.40-8.26-26.56-11.31-32.7785.3783.66-15.86-94.262.69-1.360.9694--76.2389.4561.08---13.29--
UCB SA5.85bn257.24m38.44bn9.08k149.893.9138.406.581.231.2327.9247.190.35181.714.26600,462.401.555.031.886.2867.8072.214.4012.660.78063.150.253436.44-4.802.54-18.33-15.41-1.512.36
Haleon PLC14.53bn1.56bn42.51bn24.00k17.25--174.952.930.21060.21061.44--------468,333.30--------61.94--11.21----7.59----4.09---1.04------
Takeda Pharmaceutical Co Ltd (ADR)29.78bn1.90bn43.89bn49.28k23.130.96356.391.470.59590.59599.3814.300.30881.316.25604,390.901.971.652.351.9766.0568.056.386.060.77393.080.4219128.425.8715.25-54.561.2829.09--
Jiangsu Hengrui Pharmaceuticals Co Ltd3.62bn758.92m43.98bn19.61k58.247.21--12.150.84990.84994.066.860.571.574.601,325,555.0011.9413.6812.9915.2084.8885.8720.9420.018.34--0.00223.777.265.5510.141.1422.909.45
Sun Pharmaceutical Industries Ltd5.96bn1.31bn51.44bn43.00k39.246.2831.728.6346.1246.12209.89288.060.60051.054.1511,699,470.0013.297.7716.9210.8579.1571.5922.1414.232.09--0.035838.6410.5110.7813.0129.15-7.2837.47
Daiichi Sankyo Co Ltd11.52bn1.64bn62.11bn18.73k37.215.6930.095.39130.86130.86918.60855.860.59131.013.7393,883,960.008.434.9910.516.1476.1169.1014.269.942.24--0.058951.8725.2811.4985.9016.6713.0116.47
Data as of Nov 09 2024. Currency figures normalised to Takeda Pharmaceutical Co Ltd's reporting currency: US Dollar USD

Institutional shareholders

1.29%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (Global Investors)as of 30 Jun 202413.13m0.41%
Mondrian Investment Partners Ltd.as of 30 Sep 20245.09m0.16%
Millennium Management LLCas of 30 Jun 20244.35m0.14%
Parametric Portfolio Associates LLCas of 30 Jun 20243.83m0.12%
Renaissance Technologies LLCas of 30 Jun 20242.95m0.09%
Brandes Investment Partners LPas of 30 Jun 20242.64m0.08%
Strategic Advisers LLCas of 30 Jun 20242.56m0.08%
Arrowstreet Capital LPas of 30 Jun 20242.32m0.07%
Van Eck Associates Corp.as of 30 Sep 20242.18m0.07%
Goldman Sachs Asset Management LPas of 30 Jun 20241.84m0.06%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.